Shilpa Medicare received Initial Authorisation from Europe for its generic Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch, a bioequivalent version of innovator drug Neupro for 'Restless Legs Syndrome' and 'Parkinson’s' disease. The company targets a Fiscal Year 2027 launch for a market estimated at USD 222 million, marking an approval milestone for its Unit VI facility.